WallStSmart

AbbVie Inc (ABBV)vsCanadian Imperial Bank Of Commerce (CM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 125% more annual revenue ($62.82B vs $27.91B). CM leads profitability with a 33.5% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.56. CM earns a higher WallStSmart Score of 73/100 (B).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

CM

Strong Buy

73

out of 100

Grade: B

Growth: 9.3Profit: 7.5Value: 5.7Quality: 3.0
Piotroski: 5/9Altman Z: -0.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-47.7%)

Margin of Safety

-47.7%

Fair Value

$145.81

Current Price

$217.72

$71.91 premium

UndervaluedFair: $145.81Overvalued

Intrinsic value data unavailable for CM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.3/10
Market CapQuality
$368.38B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
32.2%10/10

Strong operational efficiency at 32.2%

Debt/EquityHealth
-11.0210/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.568/10

Growing faster than its price suggests

Free Cash FlowQuality
$3.56B8/10

Generating 3.6B in free cash flow

CM6 strengths · Avg: 8.8/10
Profit MarginProfitability
33.5%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
44.7%10/10

Strong operational efficiency at 44.7%

Market CapQuality
$106.24B9/10

Large-cap with strong market position

P/E RatioValuation
16.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
102.2x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-46.2%2/10

Earnings declined 46.2%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

CM4 concerns · Avg: 2.3/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

Free Cash FlowQuality
$-2.49B2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
-0.622/10

Distress zone — elevated risk

Debt/EquityHealth
2.661/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.56 suggests the stock is reasonably priced for its growth.

Bull Case : CM

The strongest argument for CM centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 33.5% and operating margin at 44.7%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 102.2x leaves little room for execution misses.

Bear Case : CM

The primary concerns for CM are PEG Ratio, Free Cash Flow, Altman Z-Score. Debt-to-equity of 2.66 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABBV profiles as a value stock while CM is a growth play — different risk/reward profiles.

CM carries more volatility with a beta of 1.30 — expect wider price swings.

CM is growing revenue faster at 16.7% — sustainability is the question.

ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.

Bottom Line

CM scores higher overall (73/100 vs 63/100), backed by strong 33.5% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Canadian Imperial Bank Of Commerce

FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA

Canadian Imperial Bank of Commerce, a diversified financial institution, offers a variety of financial products and services to personal, commercial, public sector, and institutional clients in Canada, the United States, and internationally. The company is headquartered in Toronto, Canada.

Visit Website →

Want to dig deeper into these stocks?